Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.

MLA

Dane, Faysal, et al. “Safety and Efficacy of Regorafenib in Patients with Treatment-Refractory Metastatic Colorectal Cancer in Turkey: The Single-Arm, Open-Label REGARD Study.” BMJ Open, vol. 10, no. 3, Mar. 2020, p. e027665. EBSCOhost, https://doi.org/10.1136/bmjopen-2018-027665.

APA

Dane, F., Ozgurdal, K., Yalçın, Ş., Benekli, M., Aykan, N. F., Yücel, İ., Özkan, M., Evrensel, T., Sevinç, A., Coskun, H. Ş., Sanli, U. A., Kara, I. O., & Yumuk, P. F. (2020). Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. BMJ Open, 10(3), e027665. https://doi.org/10.1136/bmjopen-2018-027665

Chicago

Dane, Faysal, Kirhan Ozgurdal, Şuayib Yalçın, Mustafa Benekli, Nuri Faruk Aykan, İdris Yücel, Metin Özkan, et al. 2020. “Safety and Efficacy of Regorafenib in Patients with Treatment-Refractory Metastatic Colorectal Cancer in Turkey: The Single-Arm, Open-Label REGARD Study.” BMJ Open 10 (3): e027665. doi:10.1136/bmjopen-2018-027665.